The assignment of an International Nonproprietary Name (INN) confirms that the compound has a unique chemical identity and establishes an internationally recognized name for use by researchers and healthcare professionals worldwide. The assignment also means that the company will henceforth refer to the drug candidate as linepemat in its communications.

Linepemat is being developed as a potential first-in-class treatment for apathy associated with Parkinson’s disease and other neurological conditions. Apathy is characterized by indifference, resignation and a lack of response to what is happening in the outside world. The condition often leads to significant disability affecting a substantial proportion of people living with Parkinson's disease and other neurodegenerative diseases. Currently, there are no drugs on the market to treat apathy.

The LIFT-PD clinical study is being conducted under IRLAB’s leadership and is fully funded by Otsuka. IRLAB retains full ownership of linepemat. Otsuka has the opportunity to elect to expand the collaboration upon the occurrence of certain triggering events, subject to negotiations of a new agreement. The first results from the LIFT-PD study are expected to be reported in mid-2027.

“The assignment of the INN name linepemat represents an important milestone in the development of the drug candidate and a clear recognition of the compound’s unique properties. Apathy is one of the most debilitating symptoms of Parkinson’s disease, as well as several other neurological and psychiatric disorders. With linepemat, we aim to address a significant unmet medical need for which no approved treatment currently exists, and we look forward to presenting the first results from the LIFT-PD study in 2027,” says Kristina Torfgård, CEO of IRLAB